Probiotics Prescribed With Helicobacter pylori Eradication
Therapy in Europe: Usage Pattern, Effectiveness, and Safety.
Results From the European Registry on Helicobacter pylori
Management (Hp-EuReg)

J 2025

Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg)

DIEGO, Casas Deza; Javier ALCEDO; Miguel LAFUENTE; F Javier LOPEZ; Angeles PEREZ-AISA et al.

Základní údaje

Originální název

Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg)

Autoři

Vydání

American Journal of Gastroenterology, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2025, 0002-9270

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30219 Gastroenterology and hepatology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.600 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00143159

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

probiotics; Helicobacter pylori; eradication therapy; effectiveness; safety; Lactobacillus; Bifidobacterium; Saccharomyces

Štítky

14110223, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 1. 2026 09:57, Mgr. Tereza Miškechová

Anotace

V originále

INTRODUCTION:To evaluate the prescription patterns, effectiveness, and safety of adding probiotics to Helicobacter pylori eradication therapy, in Europe.METHODS:International, prospective, noninterventional registry of the clinical practice of the European gastroenterologists. Data were collected and quality reviewed until March 2021 at AEG-REDCap. The effectiveness was evaluated by modified intention-to-treat analysis, differentiating by geographic areas. Adverse events (AEs) were categorized as mild, moderate, and severe.RESULTS:Overall, 36,699 treatments were recorded, where 8,233 (22%) were prescribed with probiotics. Probiotics use was associated with higher effectiveness in the overall analysis (odds ratio [OR] 1.631, 95% confidence interval [CI] 1.456-1.828), as well as in triple (OR 1.702, 95% CI 1.403-2.065), quadruple (OR 1.383, 95% CI 0.996-1.920), bismuth quadruple (OR 1.248, 95% CI 1.003-1.554), and sequential therapies (OR 3.690, 95% CI 2.686-5.069). Lactobacillus genus was associated with a higher therapy effectiveness in Eastern Europe when triple (OR 2.625, 95% CI 1.911-3.606) and bismuth quadruple (OR 1.587, 95% CI 1.117-2.254) first-line therapies were prescribed. In Central Europe, the use of probiotics was associated with a decrease in both the overall incidence of AEs (OR 0.656, 95% CI 0.516-0.888) and severe AEs (OR 0.312, 95% CI 0.217-0.449). Bifidobacterium genus was associated with lower overall (OR 0.725, 95% CI 0.592-0.888) and severe (OR 0.254, 95% CI 0.185-0.347) AEs, and Saccharomyces was associated with reduced overall (OR 0.54, 95% CI 0.32-0.91) and severe (OR 0.257, 95% CI 0.123-0.536) AEs under quadruple-bismuth regimen.DISCUSSION:In Europe, the use of probiotics was associated with higher effectiveness and safety of H. pylori eradication therapy. Lactobacillus improved treatment effectiveness, whereas Bifidobacterium and Saccharomyces were associated with a better safety profile.

Citovat

DIEGO, Casas Deza; Javier ALCEDO; Miguel LAFUENTE; F Javier LOPEZ; Angeles PEREZ-AISA; Matteo PAVONI; Bojan TEPES; Laimas JONAITIS; Manuel CASTRO-FERNANDEZ; Manuel PABON-CARRASCO; Alma KECO-HUERGA; Irina VOYNOVAN; Luis BUJANDA; Alfredo J LUCENDO; Brglez Jurecic NATASA; Maja DENKOVSKI; Ludmila VOLOGZANINA; Luis RODRIGO; Samuel J MARTINEZ-DOMINGUEZ; Galyna FADIEIENKO; Jose M HUGUET; Rustam ABDULKHAKOV; Sayar R ABDULKHAKOV; Noelia ALCAIDE; Benito VELAYOS; Luis HERNANDEZ; Dmitry S BORDIN; Antonio GASBARRINI; Juozas KUPCINSKAS; Gulustan BABAYEVA; Oleksiy GRIDNYEV; Marcis LEJA; Theodore ROKKAS; Ricardo MARCOS-PINTO; Frode LERANG; Doron BOLTIN; Antonio MESTROVIC; Sinead M SMITH; Marino VENERITO; Lyudmila BOYANOVA; Vladimir MILIVOJEVIC; Michael DOULBERIS; Lumír KUNOVSKÝ; Pablo PARRA; Anna CANO-CATALA; Leticia MOREIRA; Olga P NYSSEN; Francis MEGRAUD; Colm O MORAIN a Javier P GISBERT. Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg). American Journal of Gastroenterology. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2025, roč. 120, č. 11, s. 2644-2659. ISSN 0002-9270. Dostupné z: https://doi.org/10.14309/ajg.0000000000003351.

@article{2544629,
   author = {Diego, Casas Deza and Alcedo, Javier and Lafuente, Miguel and Lopez, F Javier and PerezandAisa, Angeles and Pavoni, Matteo and Tepes, Bojan and Jonaitis, Laimas and CastroandFernandez, Manuel and PabonandCarrasco, Manuel and KecoandHuerga, Alma and Voynovan, Irina and Bujanda, Luis and Lucendo, Alfredo J and Natasa, Brglez Jurecic and Denkovski, Maja and Vologzanina, Ludmila and Rodrigo, Luis and MartinezandDominguez, Samuel J and Fadieienko, Galyna and Huguet, Jose M and Abdulkhakov, Rustam and Abdulkhakov, Sayar R and Alcaide, Noelia and Velayos, Benito and Hernandez, Luis and Bordin, Dmitry S and Gasbarrini, Antonio and Kupcinskas, Juozas and Babayeva, Gulustan and Gridnyev, Oleksiy and Leja, Marcis and Rokkas, Theodore and MarcosandPinto, Ricardo and Lerang, Frode and Boltin, Doron and Mestrovic, Antonio and Smith, Sinead M and Venerito, Marino and Boyanova, Lyudmila and Milivojevic, Vladimir and Doulberis, Michael and Kunovský, Lumír and Parra, Pablo and CanoandCatala, Anna and Moreira, Leticia and Nyssen, Olga P and Megraud, Francis and Morain, Colm O and Gisbert, Javier P},
   article_location = {PHILADELPHIA},
   article_number = {11},
   doi = {https://doi.org/10.14309/ajg.0000000000003351},
   keywords = {probiotics; Helicobacter pylori; eradication therapy; effectiveness; safety; Lactobacillus; Bifidobacterium; Saccharomyces},
   language = {eng},
   issn = {0002-9270},
   journal = {American Journal of Gastroenterology},
   title = {Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg)},
   url = {https://journals.lww.com/ajg/abstract/2025/11000/probiotics_prescribed_with_helicobacter_pylori.32.aspx},
   volume = {120},
   year = {2025}
}

TY  - JOUR
ID  - 2544629
AU  - Diego, Casas Deza - Alcedo, Javier - Lafuente, Miguel - Lopez, F Javier - Perez-Aisa, Angeles - Pavoni, Matteo - Tepes, Bojan - Jonaitis, Laimas - Castro-Fernandez, Manuel - Pabon-Carrasco, Manuel - Keco-Huerga, Alma - Voynovan, Irina - Bujanda, Luis - Lucendo, Alfredo J - Natasa, Brglez Jurecic - Denkovski, Maja - Vologzanina, Ludmila - Rodrigo, Luis - Martinez-Dominguez, Samuel J - Fadieienko, Galyna - Huguet, Jose M - Abdulkhakov, Rustam - Abdulkhakov, Sayar R - Alcaide, Noelia - Velayos, Benito - Hernandez, Luis - Bordin, Dmitry S - Gasbarrini, Antonio - Kupcinskas, Juozas - Babayeva, Gulustan - Gridnyev, Oleksiy - Leja, Marcis - Rokkas, Theodore - Marcos-Pinto, Ricardo - Lerang, Frode - Boltin, Doron - Mestrovic, Antonio - Smith, Sinead M - Venerito, Marino - Boyanova, Lyudmila - Milivojevic, Vladimir - Doulberis, Michael - Kunovský, Lumír - Parra, Pablo - Cano-Catala, Anna - Moreira, Leticia - Nyssen, Olga P - Megraud, Francis - Morain, Colm O - Gisbert, Javier P
PY  - 2025
TI  - Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg)
JF  - American Journal of Gastroenterology
VL  - 120
IS  - 11
SP  - 2644-2659
EP  - 2644-2659
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 00029270
KW  - probiotics
KW  - Helicobacter pylori
KW  - eradication therapy
KW  - effectiveness
KW  - safety
KW  - Lactobacillus
KW  - Bifidobacterium
KW  - Saccharomyces
UR  - https://journals.lww.com/ajg/abstract/2025/11000/probiotics_prescribed_with_helicobacter_pylori.32.aspx
N2  - INTRODUCTION:To evaluate the prescription patterns, effectiveness, and safety of adding probiotics to Helicobacter pylori eradication therapy, in Europe.METHODS:International, prospective, noninterventional registry of the clinical practice of the European gastroenterologists. Data were collected and quality reviewed until March 2021 at AEG-REDCap. The effectiveness was evaluated by modified intention-to-treat analysis, differentiating by geographic areas. Adverse events (AEs) were categorized as mild, moderate, and severe.RESULTS:Overall, 36,699 treatments were recorded, where 8,233 (22%) were prescribed with probiotics. Probiotics use was associated with higher effectiveness in the overall analysis (odds ratio [OR] 1.631, 95% confidence interval [CI] 1.456-1.828), as well as in triple (OR 1.702, 95% CI 1.403-2.065), quadruple (OR 1.383, 95% CI 0.996-1.920), bismuth quadruple (OR 1.248, 95% CI 1.003-1.554), and sequential therapies (OR 3.690, 95% CI 2.686-5.069). Lactobacillus genus was associated with a higher therapy effectiveness in Eastern Europe when triple (OR 2.625, 95% CI 1.911-3.606) and bismuth quadruple (OR 1.587, 95% CI 1.117-2.254) first-line therapies were prescribed. In Central Europe, the use of probiotics was associated with a decrease in both the overall incidence of AEs (OR 0.656, 95% CI 0.516-0.888) and severe AEs (OR 0.312, 95% CI 0.217-0.449). Bifidobacterium genus was associated with lower overall (OR 0.725, 95% CI 0.592-0.888) and severe (OR 0.254, 95% CI 0.185-0.347) AEs, and Saccharomyces was associated with reduced overall (OR 0.54, 95% CI 0.32-0.91) and severe (OR 0.257, 95% CI 0.123-0.536) AEs under quadruple-bismuth regimen.DISCUSSION:In Europe, the use of probiotics was associated with higher effectiveness and safety of H. pylori eradication therapy. Lactobacillus improved treatment effectiveness, whereas Bifidobacterium and Saccharomyces were associated with a better safety profile.
ER  -

DIEGO, Casas Deza; Javier ALCEDO; Miguel LAFUENTE; F Javier LOPEZ; Angeles PEREZ-AISA; Matteo PAVONI; Bojan TEPES; Laimas JONAITIS; Manuel CASTRO-FERNANDEZ; Manuel PABON-CARRASCO; Alma KECO-HUERGA; Irina VOYNOVAN; Luis BUJANDA; Alfredo J LUCENDO; Brglez Jurecic NATASA; Maja DENKOVSKI; Ludmila VOLOGZANINA; Luis RODRIGO; Samuel J MARTINEZ-DOMINGUEZ; Galyna FADIEIENKO; Jose M HUGUET; Rustam ABDULKHAKOV; Sayar R ABDULKHAKOV; Noelia ALCAIDE; Benito VELAYOS; Luis HERNANDEZ; Dmitry S BORDIN; Antonio GASBARRINI; Juozas KUPCINSKAS; Gulustan BABAYEVA; Oleksiy GRIDNYEV; Marcis LEJA; Theodore ROKKAS; Ricardo MARCOS-PINTO; Frode LERANG; Doron BOLTIN; Antonio MESTROVIC; Sinead M SMITH; Marino VENERITO; Lyudmila BOYANOVA; Vladimir MILIVOJEVIC; Michael DOULBERIS; Lumír KUNOVSKÝ; Pablo PARRA; Anna CANO-CATALA; Leticia MOREIRA; Olga P NYSSEN; Francis MEGRAUD; Colm O MORAIN a Javier P GISBERT. Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg). \textit{American Journal of Gastroenterology}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{} WILKINS, 2025, roč.~120, č.~11, s.~2644-2659. ISSN~0002-9270. Dostupné z: https://doi.org/10.14309/ajg.0000000000003351.

Přehled o publikaci